Terry Coursey

Dr. Terry Coursey


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
TCTerry Coursey
Terry Coursey
RWRonald A. Wassel
Ronald A. Wassel
AQAlexander B. Quiambao
Alexander B. Quiambao
RFRafal A. Farjo
Rafal A. Farjo
Purpose: To determine if a Microemulsion Drug Ocular Penetration System (MiDROPS) formulation of cyclosporine A (CsA) delivers more drug and is more efficacious for treatment of dry eye disease (DED) than the current clinical formulation. Methods: Tissue distribution of CsA was quantified by liquid chromatography with tandem mass spectrometry (LC-MS/MS). To assess tolerability, CsA-MiDROPS (0.1%) was applied to the eyes of rabbits twice per day for 14 days and assessed using ophthalmoscopic examinations. Mice were exposed to desiccating stress for 10 days and received daily topical instillation of the vehicle or test agent. Cornea staining was done to quantify corneal permeability. Histologic quantification of goblet cell (GC) density and CD4+ T-cell infiltration in the conjunctiva was performed. Results: Ophthalmic distribution studies indicate significantly increased drug concentration with CsA-MiDROPS compared with Restasis. CsA-MiDROPS is well tolerated with little toxicity in a 2-week tolerability study. In the DED model, both 0.05% and 0.1% CsA-MiDROPS conferred a significant effect and were more effective than Restasis for treating experimental DED when dosed twice per day. As compared with Restasis dosed twice per day, 0.1% CsA-MiDROPS dosed once per day demonstrated superiority. Conclusions: CsA-MiDROPS showed superior drug delivery and efficacy compared with other clinical formulations. As this product is simple to produce and needs to be only applied once daily, the clinical development of CsA-MiDROPS will help to reduce societal and patient burdens by lowering drug costs and accelerating/improving the activity of CsA. Translational Relevance: MiDROPS has broad application concerning the ophthalmic development of lipophilic small molecule therapeutics.

10 December 2022 in The Ocular Surface
Verified
Journal Article
Closed access
MAMarwan Ali
Marwan Ali
DSDhara Shah
Dhara Shah
TCTerry Coursey
Terry Coursey
SLSang Min Lee
Sang Min Lee
ABArun Balasubramaniam
Arun Balasubramaniam
VAVinay K Aakalu
Vinay K Aakalu